Therapeutic resistance and hematological tumors
Sureda’s & Farre’s Lab

The lab is interested in improving the understanding of the molecular mechanisms leading to the progression and therapeutic resistance of multiple myeloma, including extramedullary disease, Hodgkin lymphoma and aggressive non-Hodgkin B and T lymphomas. 

To develop these lines of research, we use patient samples and advanced preclinical models for therapeutic, mechanistic and functional studies. We have developed the technology to generate murine models derived from patients by orthotopic implantation (orthotopic PDX) and 2D/3D cultures that we can humanize using components of the human immune system (from the same patient from whom the model has been derived, when possible). Additionally, we are involved in a project that is developing humanized nanomedicines as a new therapeutic strategy for acute myeloid leukemia.

Our group is integrated by professionals from the Clinical Hematology Service of ICO/Hospitalet, the ProCURE/ICO Program and the Pathology Service of the Hospital of Bellvitge. Within the Hematology Service of the ICO Hospitalet, one of our main objectives is to promote translational research training for the professionals of the Service, generating opportunities for the completion of doctoral theses and stimulating new scientific leadership as well as to attract talent with a mixed clinical/researcher profile for the Service.